This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Dec 1;33(34):3990-2.

doi: 10.1200/JCO.2015.63.7793. Epub 2015 Oct 12.

Hitting the Target in BRAF-Mutant Colorectal Cancer

Ankur K Nagaraja¹, Adam J Bass²

Affiliations

Affiliations

¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston; and Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA adam_bass@dfci.harvard.edu.

PMID: 26460302
DOI: 10.1200/JCO.2015.63.7793

Editorial

Hitting the Target in BRAF-Mutant Colorectal Cancer

Ankur K Nagaraja et al. J Clin Oncol. 2015.

. 2015 Dec 1;33(34):3990-2.

doi: 10.1200/JCO.2015.63.7793. Epub 2015 Oct 12.

Authors

Ankur K Nagaraja¹, Adam J Bass²

Affiliations

¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston; and Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA adam_bass@dfci.harvard.edu.

PMID: 26460302
DOI: 10.1200/JCO.2015.63.7793

No abstract available

PubMed Disclaimer

Comment on

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Corcoran RB, et al. J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21. J Clin Oncol. 2015. PMID: 26392102 Free PMC article. Clinical Trial.
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Kopetz S, et al. J Clin Oncol. 2015 Dec 1;33(34):4032-8. doi: 10.1200/JCO.2015.63.2497. Epub 2015 Oct 12. J Clin Oncol. 2015. PMID: 26460303 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program